Focusing on the initiation of treatment for newly diagnosed patients with CML, Jorge E. Cortes, MD, details important factors to consider when starting treatment and Claire Saxton discusses strategies ...

Results from the phase 3 ENDURE trial (NCT03117816), newly published in Leukemia, demonstrate that ropeginterferon alfa-2b ...

Patients with chronic myeloid leukemia should be upfront with their care team about how treatment side effects are affecting their daily functioning. When discussing side effects from chronic myeloid ...

Dr Lindsay Rein comments on significant advancements in CML treatment presented at ASH 2024, particularly the approval of asciminib in both the frontline and second-line settings. This new treatment ...

The survival prognosis for patients with chronic phase CML has greatly improved since the introduction of TKIs, with some studies showing life expectancy close to the general population. Nonetheless, ...

A recent study in the British Journal of Haematology by Irani and colleagues suggests that an effector-suppressor score, which is calculated using absolute natural killer (NK) cell, FoxP3 + regulatory ...

The leading Chronic Myeloid Leukemia Companies such as Kartos Therapeutics, AOP Orphan Pharmaceuticals, Biokine Therapeutics, ...

Treatment-free remission (TFR) may be feasible in many patients with chronic myeloid leukaemia (CML), say researchers who set out clinical and logistical requirements for discontinuing tyrosine kinase ...

Please provide your email address to receive an email when new articles are posted on . In this video, Eric Winer, MD, discusses the results of research into chronic myeloid leukemia presented at ASCO ...

CHICAGO — Asciminib demonstrated superior efficacy to standard first-line therapies for certain patients with newly diagnosed chronic myeloid leukemia, according to study results presented at ASCO ...

Shares of Enliven Therapeutics (NASDAQ:ELVN) climbed 7% on Thursday after the company released positive early results from a ...